Physician profile
Vicky A Spiller
NPI 1891461083
$10,199.76
in general payments reported to CMS, 2019-2025
23 companies · $1,758 in 2025
The $1,758 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Registered Nurse) providers received nationally (typical 2025 total: $137).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,417 · 2023: $2,476 · 2024: $3,548 · 2025: $1,758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,771 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,770.82 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,896.40 | 2022-2025 | Caplyta |
| Abbvie INC. | $1,545.05 | 2022-2025 | |
| Alkermes, INC. | $1,100.63 | 2022-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $655.03 | 2022-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $610.93 | 2023-2025 | Austedo Xr, Uzedy, Austedo |
| Neurocrine Biosciences, INC. | $559.23 | 2023-2025 | Ingrezza |
| Bausch Health US, LLC | $534.89 | 2022-2025 | Aplenzin, Wellbutrin |
| Takeda Pharmaceuticals U.S.A., INC. | $505.61 | 2022-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $407.21 | 2022 | |
| Lundbeck LLC | $386.06 | 2022-2025 | Rexulti, Abilify Asimtufii |
| Tris Pharma INC | $379.74 | 2022-2025 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $304.93 | 2022-2025 | Spravato, Invega Sustenna |
| Corium, LLC | $298.46 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $251.68 | 2023-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $231.52 | 2022-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $152.34 | 2022-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $123.22 | 2024-2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $83.20 | 2022-2023 | Quviviq |
| Neos Therapeutics, Lp | $65.74 | 2024 | Adzenys Xr-Odt |
| Merck Sharp & Dohme LLC | $45.12 | 2022-2023 | Belsomra |
| Biogen, INC. | $29.89 | 2025 | Zurzuvae |
| Indivior INC. | $16.83 | 2022 | |
| Jazz Pharmaceuticals INC. | $16.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vicky Spiller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.